DOCSLIB.ORG

Proton Therapy Is Here a New Standard of Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proton Therapy Is Here a New Standard of Care PROMISE& PROGRESS THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS Proton Therapy Is Here A New Standard of Care 2020/2021 & Care. P P Collaboration. THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT Innovation. JOHNS HOPKINS Promise & Progress PROTON THERAPY IS HERE. The new have the most advanced pencil beam, is published by Johns Hopkins National Proton Center at which paints tumors with cancer cell- The Sidney Kimmel Comprehensive Cancer Center Sibley Memorial Hospital is built upon a killing energy layer by layer, staying within at Johns Hopkins long and rich tradition of excellence in the boundaries of the tumor. The Office of Public Affairs Baltimore, Maryland radiation oncology, bringing nearly a beam adjusts to differences throughout a 410-955-1287 half-century of cancer discovery and tumor to provide the right amount of William G. Nelson, M.D., Ph.D. clinical progress to proton therapy. energy to every different area of the tumor. Director One size doesn’t fit all. Every patient, Amy Mone every cancer, is different, so we are Director of Public Affairs ushering in the most advanced tumor Valerie Matthews Mehl monitoring that makes the already safe Editor and Sr. Writer [email protected] and targeted pencil beam patient-specific Megan Mattis and even more tumor-specific. Advanced Photography Assistant imaging and sophisticated data mining Howard Korn, Joe Rubino, Tim Bloomquist will make complex comparisons of Feature Photography photon and proton therapies to ensure For additional copies of this each patient receives the therapy that is publication or further information best suited to his or her unique cancer. about the Kimmel Cancer Center, We have the world’s leading experts please call 410-955-1287 across all disciplines and specialties or email [email protected]. working in collaboration. This includes MSK Partners, Inc. a collaboration with Children’s National Design and Production Hospital to create one of the largest pediatric radiation oncology programs in the country. Few other centers can claim Connecting this level of expertise. We know cancer Promise to Progress It’s striking that this technology has and proton therapy. That is the Johns On the Web been around for more than 40 years but Hopkins difference. There are centers that CONNECT WITH US HOPKINSCANCER.ORG has never really been tested in the can deliver proton therapy, and then there research setting. This is what sets us apart are centers like ours that combine the FACEBOOK.COM/HOPKINSKIMMEL from other centers. We ask the tough highest level of cancer care with YOUTUBE.COM/HOPKINSKIMMEL questions because we are prepared to go scientific innovation to make sure the after the answers. With a dedicated cancer medicine we deliver is the best TWITTER.COM/HOPKINSKIMMEL proton research laboratory, our experts medicine for each patient. Our new INSTAGRAM.COM/HOPKINSKIMMEL are ready to do the hard work and gather National Proton Center enhances our mis- the much-needed evidence to guide when sion of curing cancer and changing lives. PODCASTS: HOPKINSKIMMEL.LIBSYN.COM and how proton therapy is best used. CANCER-MATTERS.BLOGS.HOPKINSMEDICINE.ORG We waited until the technology was OUR-CANCER.BLOGS.HOPKINSMEDICINE.ORG right to bring proton therapy to Johns William G. Nelson, M.D., Ph.D. Hopkins, and when we did, we made Marion I. Knott Professor and Director FOR APPOINTMENTS AND OTHER INFORMATION, CALL 410-955-5222 it better, customizing it with our own The Sidney Kimmel Comprehensive inventions. Our proton therapy center will Cancer Center at Johns Hopkins ©2019 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2 PROMISE & PROGRESS Proton Therapy Is Here Johns Hopkins excellence is setting a new standard of care Technology without advanced and compassionate care is The translational ingenuity that merges science alone. But technology in an environment of compas- laboratory discovery with clinical care thrives in the Kimmel Cancer Center. It sionate care, discovery and multispecialty collaboration was engaged throughout the planning focused on improving the lives of patients is cancer medicine. and construction of our proton center. As This is the hallmark of Johns Hopkins and the Kimmel Cancer a result, it is one of the most comprehen- sive in the world, one of the very few sep- Center, where innovation that exceeds the standard is the arate, dedicated rooms for research, norm. The result is an unsurpassed level of expertise in radiation pediatric patient care and adult patient oncology, molecular radiation sciences, physics, surgical care. Proton therapy has raised many oncology, medical oncology, cancer biology, engineering, questions about for whom and how it is best used. Our experts are answering quantitative sciences and more that Johns Hopkins Medicine those questions. They are providing the brings to proton therapy. This level of knowledge and “why” and “when” of proton therapy. multispecialty collaboration are fundamentally what set the Despite commercial advertising to the contrary, proton therapy is not new, and Johns Hopkins National Proton Center apart from most other the science is far from settled. “Although proton centers across the U.S. Expertise matters because the it has been around for a long time, it is real value of proton therapy is in the specialists who develop very much in its infancy in terms of ex- and use it. ploration and potential,” says Akila Viswanathan, interim director of the Department of Radiation Oncology and Proton therapy may be a rare commodity, cancer discovery and clinical progress to Molecular Radiation Sciences. with less than 40 centers in the U.S., but proton therapy.” this level of expertise is even rarer. The COLLABORATION Kimmel Cancer Center is among the very Although this technology provides new few that will combine cancer treatment opportunity to move cancer science and Proton therapy has excellence across all disciplines with medicine forward, not all proton ther- proton therapy excellence. apy is created equal. We are not simply raised many questions users and deliverers of proton therapy. about for whom and “Patients and families need the team that Our scientists are also inventors, knows the most about the tumor. You driving, testing and improving the how it is best used. need to know cancer, not just proton technology to create a proton facility Our experts are helping therapy. That is a differentiator for us,” unlike any other. Building upon a says William Nelson, Director of the lengthy history and strong foundation answer those questions. Kimmel Cancer Center. “We bring the of pioneering discoveries in radiation They are providing the full complement of Johns Hopkins therapy, this center has the technology expertise, spanning programs and to deliver the most advanced and “why” and “when” of departments, and nearly a half-century of patient-centered care. proton therapy. THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER at JOHNS HOPKINS 3 The Synchrotron HOW IT WORKS A synchrotron is a type of particle accelerator used to accelerate protons for Inside Our Proton use in proton therapy. It is 26 feet in diameter and Therapy Center composed of a ring of small magnets. Protons are The proton is small, but it takes big injected into the ring and begin traveling around machinery to generate and move these the ring at great speeds, subatomic particles for treatment. about 10 million times per second. Put another way, the speed of the protons is so fast, it could circle around the earth five times in one second. It is advanced technology over earlier generations of proton therapy because it can produce beams of a Gantries wide range of energies and Protons travel down reduces the risk of unnec- magnetic devices into essary and unwanted the treatment rooms. radiation to the patient. A 360-degree, rotating, 30-foot-diameter iron framework, called a gantry, controls the speed and direction of protons. It allows radiation oncologists to Pencil Beam Scanning direct the beam at any This new technology funnels angle and deliver the the protons into a narrow proton beam with beam—just a pencil tip’s pinpoint accuracy Respiratory Gating to a patient’s cancer. width—coming out of the The slightest motion proton therapy machine can cause tumors hundreds of times per Our center has four of to move. Our proton these, with one gantry second, scanning the tumor therapy beam tracks back and forth and up and dedicated exclusively directly to the tumor, for pediatric patients down, just to the edges of stopping if the tumor the tumor, to paint it layer by and another for much- shifts with the patient’s needed research. layer with the cancer-killing breathing and starting proton beam. Our advanced up again when the technology is intensity mod- beam and tumor are ulated, making it possible aligned. to deliver varying degrees of energy targeted to the specific composition of each area of the tumor. On-Board Imaging Ours will be among the first to have on-board imaging. Plans for a CT Couch, invented by medical physics Director John Wong in collaboration with Hitachi, will provide a built-in CT scanner that merges images of the cancer taken during treatment planning with ones taken the day of treatment to verify that the tumor being treated has not changed or moved. It facilitates precision treatment within one-tenth of 1 millimeter accuracy. 4 PROMISE & PROGRESS As a result, what truly is new in proton problem, Wong invented the Small Ani- and where can we reduce toxicity? therapy is what the Johns Hopkins mal Radiation Research Platform Where are we not getting such benefit National Proton Center brings: the labo- (SARRP), a miniaturized version of the and can let go? This is an area that is ratory and clinical research to make it machines used to treat humans that is for lacking, and our center can begin to get better and to advance its use as a tool of animal research and potentially other to the answers.” The Johns Hopkins precision medicine.
Load more

Recommended publications
  • The Five Common Particles
    The Five Common Particles The world around you consists of only three particles: protons, neutrons, and electrons. Protons and neutrons form the nuclei of atoms, and electrons glue everything together and create chemicals and materials. Along with the photon and the neutrino, these particles are essentially the only ones that exist in our solar system, because all the other subatomic particles have half-lives of typically 10-9 second or less, and vanish almost the instant they are created by nuclear reactions in the Sun, etc. Particles interact via the four fundamental forces of nature. Some basic properties of these forces are summarized below. (Other aspects of the fundamental forces are also discussed in the Summary of Particle Physics document on this web site.) Force Range Common Particles It Affects Conserved Quantity gravity infinite neutron, proton, electron, neutrino, photon mass-energy electromagnetic infinite proton, electron, photon charge -14 strong nuclear force ≈ 10 m neutron, proton baryon number -15 weak nuclear force ≈ 10 m neutron, proton, electron, neutrino lepton number Every particle in nature has specific values of all four of the conserved quantities associated with each force. The values for the five common particles are: Particle Rest Mass1 Charge2 Baryon # Lepton # proton 938.3 MeV/c2 +1 e +1 0 neutron 939.6 MeV/c2 0 +1 0 electron 0.511 MeV/c2 -1 e 0 +1 neutrino ≈ 1 eV/c2 0 0 +1 photon 0 eV/c2 0 0 0 1) MeV = mega-electron-volt = 106 eV. It is customary in particle physics to measure the mass of a particle in terms of how much energy it would represent if it were converted via E = mc2.
    [Show full text]
  • QUEST Provider Bulletin
    HMSA Provider Bulletin HMS A ’ S P L an fo R Q U E S T M embe R S Bulletin Q08-01 January 15, 2008 A MESSAGE FROM OUR appointments, ensuring the collection and forwarding of MEDICAL DIRECTOR necessary information, obtaining prior authorizations, educating the parents, and following up to ensure appointments are kept is Children with Special Health Care Needs guaranteed to be difficult and time consuming. Children with chronic illnesses are Other examples include children with diabetes, congenital heart challenging for pediatricians and other defects, seizure disorders, asthma, cancer (even if in remission), primary care providers entrusted with and juvenile rheumatoid arthritis. Also included are children their care. This is especially so for with multiple diagnoses, related or otherwise. those children whose management The Hawaii Department of Health has a service dedicated to requires the services of various assisting such children, their families and their caregivers. This medical specialists, allied health care is the Children with Special Health Needs Program, under the providers, organizations, and institutions. A child with Family Health Services Division. Children and youth under 21 a cleft palate, for example, may require the services of years of age residing in Hawaii are eligible if they have chronic an ENT surgeon, oral surgeon, dentist, audiologist, health conditions lasting (or expected to last) at least one year, speech therapist, DME provider (for hearing aids), for which specialized medical care is required. and the Department of Education. Locating these The Children with Special Health Needs Program can assist providers, making the necessary referrals, coordinating QUEST members who are having difficulty in coordinating or obtaining health care services, or who cannot obtain certain Happy New Year 2008 services through QUEST, with the following: IN THIS ISSUE: • Coordination of health care referrals and appointments.
    [Show full text]
  • Internal Radiation Therapy, Places Radioactive Material Directly Inside Or Next to the Tumor
    Brachytherapy Brachytherapy is a type of radiation therapy used to treat cancer. It places radioactive sources inside the patient to kill cancer cells and shrink tumors. This allows your doctor to use a higher total dose of radiation to treat a smaller area in less time. Your doctor will tell you how to prepare and whether you will need medical imaging. Your doctor may use a computer program to plan your therapy. What is brachytherapy and how is it used? External beam radiation therapy (EBRT) directs high-energy x-ray beams at a tumor from outside the body. Brachytherapy, also called internal radiation therapy, places radioactive material directly inside or next to the tumor. It uses a higher total dose of radiation to treat a smaller area in less time than EBRT. Brachytherapy treats cancers throughout the body, including the: prostate - see the Prostate Cancer Treatment (https://www.radiologyinfo.org/en/info/pros_cancer) page cervix - see the Cervical Cancer Treatment (https://www.radiologyinfo.org/en/info/cervical-cancer-therapy) page head and neck - see the Head and Neck Cancer Treatment (https://www.radiologyinfo.org/en/info/hdneck) page skin breast - see the Breast Cancer Treatment (https://www.radiologyinfo.org/en/info/breast-cancer-therapy) page gallbladder uterus vagina lung - see the Lung Cancer Treatment (https://www.radiologyinfo.org/en/info/lung-cancer-therapy) page rectum eye Brachytherapy is seldom used in children. However, brachytherapy has the advantage of using a highly localized dose of radiation. This means that less radiation is delivered to surrounding tissue. This significantly decreases the risk of radiation-induced second malignancies, a serious concern in children.
    [Show full text]
  • Radiation Therapy – a Technicians Overview By: Stephanie Corsi, CVT
    Radiation Therapy – A technicians overview By: Stephanie Corsi, CVT Senior Radiation Oncology nurse, PennVet What is radiation therapy? Radiation therapy uses high-energy radiation or high energy particle (electrons) to kill cancer cells and shrink tumors. How does radiation therapy work? Radiation kills cancer cells by damaging their DNA. Cells that are rapidly dividing, like cancer cells, are more susceptible to radiation. The damage is by a high energy photon ejecting a high energy electron that then reacts with a water molecule to create charged particle, also called free radicals, within the cell that will damage the DNA. Most cells die what is called a “mitotic death”, meaning the cancer cells whose DNA is damaged beyond repair will stop dividing and die. Goal of Radiation: The purpose of radiation is to maximize the likelihood of tumor control while minimizing side-effects to the patient. Radiation may be used alone or in combination with surgery, chemotherapy, or both. “Curative” intent/ definitive therapy: This is given when the prognosis is good. The hope is that treatment will cure a cancer by eliminating a tumor and preventing recurrence. For tumors that are inherently sensitive, relatively small, and localized. Also used to treat residual cancer left behind after surgery, or before surgery to shrink a tumor. Examples: localized lymphomas, certain mast cell tumors, cutaneous squamous cell carcinomas Palliative intent: Not intended to cure, but rather relieve symptoms and reduce suffering. Given when prognosis is poor and quality of life is the primary focus. Used with bulky tumors. Examples: alleviate bone pain associated with osteosarcoma, a tumor pressing on the spine, tumors pressing on the esophagus interfering with breathing/eating, etc.
    [Show full text]
  • Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer
    2112 Review Article Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy Tiantian Guo1,2#, Liqing Zou1,2#, Jianjiao Ni1,2, Xiao Chu1,2, Zhengfei Zhu1,2,3 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 2Department of Oncology, Shanghai Medical College, 3Institute of Thoracic Oncology, Fudan University, Shanghai, China Contributions: (I) Conception and design: Z Zhu; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These two authors contributed equally to this work. Correspondence to: Zhengfei Zhu, MD. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, 200032 China. Email: [email protected]. Abstract: Significant recent advances have occurred in the use of radiation therapy for locally advanced non-small cell lung cancer (LA-NSCLC). In fact, the past few decades have seen both therapeutic gains and setbacks in the evolution of radiotherapy for LA-NSCLC. The PACIFIC trial has heralded a new era of immunotherapy and has raised important questions for future study, such as the future directions of radiation therapy for LA-NSCLC in the era of immunotherapy. Modern radiotherapy techniques such as three-dimensional (3D) conformal radiotherapy and intensity-modulated radiotherapy (IMRT) provide opportunities for improved target conformity and reduced normal-tissue exposure. However, the low-dose radiation volume brought by IMRT and its effects on the immune system deserve particular attention when combing radiotherapy and immunotherapy.
    [Show full text]
  • Clinical Outcomes and Prognostic Factors of Cyberknife Stereotactic
    Que et al. BMC Cancer (2016) 16:451 DOI 10.1186/s12885-016-2512-x RESEARCH ARTICLE Open Access Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma Jenny Que1*, Hsing-Tao Kuo2, Li-Ching Lin1, Kuei-Li Lin1, Chia-Hui Lin1, Yu-Wei Lin1 and Ching-Chieh Yang1 Abstract Background: Stereotactic body radiation therapy (SBRT) has been an emerging non-invasive treatment modality for patients with hepatocellular carcinoma (HCC) when curative treatments cannot be applied. In this study, we report our clinical experience with Cyberknife SBRT for unresectable HCC and evaluate the efficacy and clinical outcomes of this highly sophisticated treatment technology. Methods: Between 2008 and 2012, 115 patients with unresectable HCC treated with Cyberknife SBRT were retrospectively analyzed. Doses ranged from 26 Gy to 40 Gy were given in 3 to 5 fractions for 3 to 5 consecutive days. The cumulative probability of survival was calculated according to the Kaplan-Meier method and compared using log-rank test. Univariate and multivariate analysis were performed using Cox proportional hazard models. Results: The median follow-up was 15.5 months (range, 2-60 months). Based on Response Evaluation and Criteria inSolidTumors(RECIST).Wefoundthat48.7%ofpatients achieved a complete response and 40 % achieved a partial response. Median survival was 15 months (4-25 months). Overall survival (OS) at 1- and 2-years was 63. 5 %(54-71.5 %) and 41.3 % (31.6-50.6 %), respectively, while 1- and 2- years Progression-free Survival (PFS) rates were 42.8 %(33.0-52.2 %) and 38.8 % (29.0-48.4 %).
    [Show full text]
  • Accelerated Partial Breast Irradiation
    Continuing Medical Education societies regarding the definition of a Intracavitary balloon (Mammosite and Clinical evidence for partial- suitable candidate. Briefly, these include Contura) or strut-based brachytherapy breast irradiation early-stage, low-risk breast cancer: T1 or (SAVI) are another modality of breast The TARGIT, a phase III non- T2 invasive ductal breast carcinoma less brachytherapy. These devices come in The Department of Radiation Oncology offers free Continuing Medical Education credit to readers who read the inferiority trial, compared single-dose than 3 cm; estrogen positive; age greater different sizes, have single or multiple designated CME article and successfully complete a follow-up test online. You can complete the steps necessary targeted intraoperative radiotherapy than 60; and node negative12 (see Table lumens (strut-based or balloon-based to receive your AMA PRA Category 1 Credit(s)™ by visiting (TARGIT) versus fractionated external cme.utsouthwestern.edu/content/target-news- 1 for ASTRO consensus guidelines). catheters), and the entire device is placed beam radiotherapy (EBRT) for breast letter-accelerated-partial-breast-irradiation-apbi-options-and-new-horizons-em150 into the lumpectomy cavity. The lumens cancer.14 From 2000-2012, a total of Treatment options are then connected to an HDR unit, and 3,451 patients were randomized between Partial-breast radiation can be deliv- treatments are given twice daily for five APBI and whole-breast radiation in 33 ered via several different modalities, days to a dose of 34 Gy in 10 fractions. centers in 11 countries. Fifteen percent including interstitial brachytherapy, This treatment is invasive, and the device of women in the APBI arm were treated Accelerated partial breast irradiation (APBI): intracavitary brachytherapy (SAVI, stays within the lumpectomy cavity for the with additional EBRT due to adverse Contura, or Mammosite), intraopera- duration of the radiation treatments (five pathological features.
    [Show full text]
  • Standards for Radiation Oncology
    Standards for Radiation Oncology Radiation Oncology is the independent field of medicine which deals with the therapeutic applications of radiant energy and its modifiers as well as the study and management of cancer and other diseases. The American College of Radiation Oncology (ACRO) is a nonprofit professional organization whose primary purposes are to advance the science of radiation oncology, improve service to patients, study the socioeconomic aspects of the practice of radiation oncology, and provide information to and encourage continuing education for radiation oncologists, medical physicists, and persons practicing in allied professional fields. As part of its mission, the American College of Radiation Oncology has developed a Practice Accreditation Program, consisting of standards for Radiation Oncology and standards for Physics/External Beam Therapy. Accreditation is a voluntary process in which professional peers identify standards indicative of a high quality practice in a given field, and which recognizes entities that meet these high professional standards. Each standard in ACRO’s Practice Accreditation Program requires extensive peer review and the approval of the ACRO Standards Committee as well as the ACRO Board of Chancellors. The standards recognize that the safe and effective use of ionizing radiation requires specific training, skills and techniques as described in this document. The ACRO will periodically define new standards for radiation oncology practice to help advance the science of radiation oncology and to improve the quality of service to patients throughout the United States. Existing standards will be reviewed for revision or renewal as appropriate on their third anniversary or sooner, if indicated. The ACRO standards are not rules, but rather attempts to define principles of practice that are indicative of high quality care in radiation oncology.
    [Show full text]
  • (IORT) for Surgically Resected Brain Metastases: Outcome Analysis of an International Cooperative Study
    Journal of Neuro-Oncology https://doi.org/10.1007/s11060-019-03309-6 CLINICAL STUDY Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study Christopher P. Cifarelli1,3 · Stefanie Brehmer5 · John Austin Vargo2 · Joshua D. Hack3 · Klaus Henning Kahl4 · Gustavo Sarria‑Vargas6 · Frank A. Giordano6 Received: 19 August 2019 / Accepted: 5 October 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Background and objective The ideal delivery of radiation to the surgical cavity of brain metastases (BMs) remains the subject of debate. Risks of local failure (LF) and radiation necrosis (RN) have prompted a reappraisal of the timing and/or modality of this critical component of BM management. IORT delivered at the time of resection for BMs requiring surgery ofers the potential for improved local control (LC) aforded by the elimination of delay in time to initiation of radiation following surgery, decreased uncertainty in target delineation, and the possibility of dose escalation beyond that seen in stereotactic radiosurgery (SRS). This study provides a retrospective analysis with identifcation of potential predictors of outcomes. Methods Retrospective data was collected on patients treated with IORT immediately following surgical resection of BMs at three institutions according to the approval of individual IRBs. All patients were treated with 50kV portable linear accelerator using spherical applicators ranging from 1.5 to 4.0 cm. Statistical analyses were performed using IBM SPSS with endpoints of LC, DBC, incidence of RN, and overall survival (OS) and p < 0.05 considered signifcant. Results 54 patients were treated with IORT with a median age of 64 years.
    [Show full text]
  • Proton Stereotactic Body Radiation Therapy for Liver Metastases— Results of 5-Year Experience for 81 Hepatic Lesions
    1760 Original Article Proton stereotactic body radiation therapy for liver metastases— results of 5-year experience for 81 hepatic lesions Alex R. Coffman1, Daniel C. Sufficool2, Joseph I. Kang1, Chung-Tsen Hsueh3, Sasha Swenson4, Patrick Q. McGee4, Gayathri Nagaraj3, Baldev Patyal1, Mark E. Reeves5, Jerry D. Slater1, Gary Y. Yang1 1Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Department of Radiation Oncology, Kettering Health Network, Kettering, OH, USA; 3Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 4Loma Linda University School of Medicine, Loma Linda, CA, USA; 5Department of Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA Contributions: (I) Conception and design: GY Yang; (II) Administrative support: B Patyal, JD Slater, GY Yang; (III) Provision of study materials or patients: CT Hsueh, G Nagaraj, ME Reeves; (IV) Collection and assembly of data: AR Coffman, GY Yang; (V) Data analysis and interpretation: AR Coffman, GY Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Alex R. Coffman, MD. Department of Radiation Oncology, Loma Linda University Medical Center, 11234 Anderson Street, Suite B121, Loma Linda, CA 92354, USA. Email: [email protected]. Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases. Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT. LC was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1).
    [Show full text]
  • An Analysis of Vertebral Body Growth After Proton Beam Therapy for Pediatric Cancer
    cancers Article An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer Keiichiro Baba 1, Masashi Mizumoto 1,* , Yoshiko Oshiro 1,2, Shosei Shimizu 1 , Masatoshi Nakamura 1, Yuichi Hiroshima 1 , Takashi Iizumi 1, Takashi Saito 1, Haruko Numajiri 1, Kei Nakai 1 , Hitoshi Ishikawa 1,3, Toshiyuki Okumura 1, Kazushi Maruo 4 and Hideyuki Sakurai 1 1 Proton Medical Research Center, Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Ibaraki 305-8576, Japan; [email protected] (K.B.); [email protected] (Y.O.); [email protected] (S.S.); [email protected] (M.N.); [email protected] (Y.H.); [email protected] (T.I.); [email protected] (T.S.); [email protected] (H.N.); [email protected] (K.N.); [email protected] (H.I.); [email protected] (T.O.); [email protected] (H.S.) 2 Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki 305-8558, Japan 3 National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-8555, Japan 4 Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-29-853-7100; Fax: +81-29-853-7102 Simple Summary: Radiotherapy has a key role in treatment of pediatric cancer and has greatly improved survival in recent years. However, vertebrae are often included in the irradiated area, and this may affect growth after treatment.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]